Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 20,975,684 $ 24,637,295
Other receivable from joint venture 507,274 93,253
Prepaid expenses and other current assets 154,804 36,745
Total Current Assets 21,637,762 24,767,293
Investment in Joint Venture 64,387
Patent costs 1,706,192 1,577,421
Total Assets 23,408,341 26,344,714
Current Liabilities    
Accounts payable and accrued liabilities 468,706 258,056
Investee losses in excess of investment 218,263
Total Current Liabilities 468,706 476,319
Commitments and contingencies - (Note 5)
Stockholders' Equity    
Common stock, $0.001 par value, 100,000,000 authorized, 37,605,914 shares and 32,862,090 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively 37,606 32,863
Additional paid-in capital 132,813,643 129,329,674
Accumulated deficit (109,915,066) (103,497,622)
Total Stockholders' Equity 22,939,635 25,868,395
Total Liabilities and Stockholders' Equity 23,408,341 26,344,714
Convertible Series A Preferred Stock [Member]    
Stockholders' Equity    
Total Stockholders' Equity 785 813
Preferred stock, $0.001 par value, 10,000,000 authorized shares: 785 813
Convertible Series B Preferred Stock [Member]    
Stockholders' Equity    
Total Stockholders' Equity 2,667 2,667
Preferred stock, $0.001 par value, 10,000,000 authorized shares: $ 2,667 $ 2,667